Eli Lilly agreed to acquire 4E Therapeutics as it continues its non-opioid pain strategy through acquisitions. The deal gives Lilly early-stage, non-addictive pain programs built around MNK inhibitors targeting the MNK-eIF4E signaling pathway for neuropathic pain and other pain categories. The reporting notes the lead asset 4ET1103 has completed early human testing for safety, and that 4E’s pipeline also includes migraine and acute pain programs. Lilly’s interest underscores continued investor and payer pressure for chronic pain treatments that avoid opioid liabilities. The acquisition adds to a broader Lilly pattern of purchasing pipeline-stage therapeutics to refill late-stage attrition risk while expanding therapeutic variety across neuroscience and inflammation-linked pain mechanisms.